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1. Introduction
Patients undergoing elective total joint arthroplasty of the lower extremities are at particularly
high risk for venous thromboembolism (VTE). Randomized clinical trials have demonstrated
the rates of deep vein thrombosis (DVT) following total hip or knee arthroplasty in patients
not given thromboprophylaxis to be 42-57 % and 41-85%, respectively [1]. Therefore, perio‐
perative thromboprophylaxis has been a crucial part of the management of these patients for
more than 20 years. The administration of anticoagulant drugs, such as vitamin K antagonists,
unfractionated heparins, low-molecular weight heparins and a pentasaccharide, is the most
effective method of reducing the risk of VTE after major orthopedic surgical procedures. In
contrast, although the appropriate uses of these agents are assumed to only minimally increase
the bleeding tendency, higher prophylactic efficacy is naturally associated with a higher risk
of bleeding complications. The American College of Chest Physicians (ACCP) Guidelines
recently downgraded the strength of most pharmaco-prophylactic recommendations in order
to achieve a more balanced trade-off between the reduction of thrombotic events and the
increase in bleeding events. [2] However, a strong recommendation for routine use of antico‐
agulants after surgery was included in the previous edition. The American Academy of
Orthopaedic Surgeons (AAOS) Guidelines also recommend that orthopedic surgeons evaluate
patients’ risks for pulmonary embolism (PE) and serious bleeding complications and indi‐
vidualize pharmacologic prophylaxis based on a risk-benefit ratio [3,4]. However, the best way
to manage patients depending on their risk for VTE remains controversial because several
forms of thromboprophylaxis following surgery are now available.
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Approaches to assessing individual risks of hospitalized patients for VTE can be applied to
determine whether anticoagulant drugs are indicated for thromboprophylaxis [5-7]. These
assessments, however, are usually complex and difficult to use in everyday practice [8]. Also,
alternative indications limited to patients undergoing surgery are lacking, and the associations
between postoperative VTE and reported risk factors such as obesity, age or varicose veins
have not yet been adequately investigated. Only one risk factor, previous history of VTE, has
sufficient evidence indicating that some of these patients may be at even higher risk [9, 10].
Measurements of blood coagulation parameters, such as prothrombin time (PT), activated
partial thromboplastin time (aPTT), plasma levels of D-dimer, and so on, are frequently used
to assess clotting function and the coagulation state in patients. Although previous consider‐
ations of these global screening tests did not facilitate the diagnosis of thrombotic events [11,
12], recent biochemical studies of the coagulation and fibrinolysis systems have expanded the
availability of specific and sensitive tests which can detect coagulation state abnormalities.
Several different markers have been found to be elevated in clinical disorders, in which the
coagulation and fibrinolysis states are out of balance (e.g. disseminated intravascular coagu‐
lation, acute myocardial infarction, cerebral infarction, and VTE).
Some of these coagulation markers are sensitive to coagulation state changes in patients
undergoing invasive procedures. We previously examined changes in the profiles of some
coagulation markers in patients undergoing primary total hip arthroplasty (THA). According
to our results, the plasma levels of soluble fibrin (SF) and plasminogen-activator inhibitor-1
(PAI-1) sensitively represented hypercoagulable states which might be associated with
postoperative VTE, and we suggested a screening method for evaluating VTE risk in patients
undergoing THA using these two markers [13]. Although further investigation is needed, this
screening test may be useful for grouping postoperative patients into risk categories. This
chapter first provides general information about coagulation markers, which we investigated
for diagnosing VTE, and then gives a brief overview of our suggestions pertaining to the
screening test for evaluating individual postoperative VTE risk.
2. Coagulation markers associated with thrombosis
2.1. D-dimer
D-dimer is a specific fragment of a cross-linked fibrin clot that is released into the blood
when a clot is lysed by plasmin. The utility of measuring D-dimer for the diagnosis of VTE
has been extensively studied.  D-dimer is  detectable  at  levels  greater  than 500 ng/mL of
fibrinogen equivalent units in nearly all patients with VTE. In general, it is a sensitive test
but lacks specificity for the diagnosis of DVT and is, therefore, only useful when negative
[14, 15] because plasma levels of D-dimer are increased in a variety of inflammatory and
prothrombotic conditions associated with activation of coagulation, such as surgery, trauma,
and infection.
Fibrinolysis and Thrombolysis164
2.2. Thrombin-antithrombin Complex (TAT)
The activation of coagulation leads to thrombin products in plasma, but this is regulated in
part through interactions with protease inhibitors, such as antithrombin III (AT III). TAT
complexes are formed following the neutralization of thrombin by ATIII. TAT is a sensitive
marker for thrombin formation, and its elevation in plasma is suggested to alter hemostatic
activation. However, TAT formation represents only an indirect measurement of an activated
coagulation system [16], and is frequently influenced by peripheral blood sampling techniques
under venous occlusion. Thus, measurement of TAT has a low diagnostic accuracy for
thrombotic events [17], though marked and persistent TAT level increases may deserve further
investigation.
2.3. Soluble Fibrin (SF)
Activated thrombin produces fibrinogen, forming a fibrin monomer that rapidly polymerizes
to form a clot. Small amounts can dissolve and circulate in plasma as "soluble fibrin". SF
molecules have a strong tendency to polymerize and thus have a short half-life and are present
physiologically only at very low concentrations. This is why SF is regarded as a very sensitive
marker showing a hypercoagulable state when significantly elevated in plasma. The hyper‐
coagulable state is often caused by various invasive procedures, such as surgery, and plasma
levels of SF are recognized to rise rapidly during and after surgery [18, 19].
2.4. Plasminogen-activator inhibitor-1 (PAI-1)
PAI-1 is an important component of the coagulation system that down-regulates fibrinolysis
in the circulation. PAI-1 is synthesized by the endothelium and smooth muscle cells in arteries.
Elevated plasma PAI-1 in non-surgical patients has been documented in subjects who
subsequently developed vascular ischemic events [20-22]. Also, plasma levels of PAI-1 are
associated with surgical invasion, and the resultant increase in levels of the fibrinolytic
inhibitor is regarded as being a major contributor to fibrinolytic shut-down [18, 23].
2.5. Preoperative VTE risk assessment
There are numerous risk factors for VTE in surgical patients, including the type and extent
of surgery or trauma, duration of hospitalization, a history of previous VTE or malignan‐
cy, and inherited hypercoagulable states [24-27]. To prevent the development of postopera‐
tive VTE, surgical patients should be assessed for risk factors and given thromboprophylaxis
as  indicated.  According  to  the  ACCP  Guidelines,  surgical  patients,  excluding  those
undergoing orthopedic surgical procedures, can be divided into 4 risk groups (very low,
low, moderate, or high) depending on the operations being performed. Patients undergo‐
ing major orthopedic surgery,  such as THA, total  knee arthroplasty or hip fracture sur‐
gery,  are  always regarded as  being at  high risk,  and the ACCP Guidelines  recommend
postoperative anticoagulation (Grade 1B) or portable intermittent pneumatic compression
(IPC) (Grade 1C) for thromboprophylaxis.
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2.6. Postoperative VTE risk assessment according to SF and PAI-1
According to preoperative risk assessment, most patients undergoing major orthopedic
surgery will be in the “high risk” group. However, the state of hypercoagulation following
surgery may vary depending on many factors (e.g. patient responsiveness to invasive proce‐
dures, types of surgery, duration of surgery, and anesthetic technique). To assess how severe
the hypercoagulable state is in patients, acute and sensitive coagulation markers are needed.
As mentioned above, we investigated coagulation markers to evaluate their utilities for VTE
risk screening following primary THA.
We investigated 170 consecutive patients who were scheduled to undergo primary THA.
Patients were excluded if they had any of the following conditions: (a) body weight <40kg; (b)
cerebral or gastrointestinal bleeding within the previous 6 months; (c) preoperative intake of
anticoagulant or antiplatelet agents; (d) severe renal insufficiency (estimated glomerular
filtration rate (eGFR) <30 mL/min-1/1.73 m-2)[28]; (e) hepatic failure; (f) allergic to contrast
agents; or (g) coagulation or fibrinolysis disorder. All patients were operated on under general
anesthesia, and THA was performed through a minimally-invasive anterolateral approach
with the patient in the lateral decubitus position. Postoperative mobilization followed a set
protocol supervised by experienced physiotherapists. Early walking with a tolerable weight
load with crutches or a walker was performed from the day after surgery.
Blood samples were obtained from peripheral veins preoperatively, after a brief fast, and on
postoperative days 1, 3, 7, and 14. Plasma SF levels were measured with a latex photometric
immunoassay (IATRO SF II; Mitsubishi Chemical Medience Corporation, Tokyo, Japan) using
IF-43 monoclonal antibody raised against a urea-solubilized fibrin monomer. PAI-1 was
measured using a latex photometric immunoassay (LPIA-tPAI Test; Mitsubishi Chemical
Medience Corporation, Tokyo, Japan). Plasma D-dimer levels were also assayed employing a
latex photometric immunoassay (LPIA-ACE D-dimer; Mitsubishi Chemical Medience
Corporation, Tokyo, Japan). The normal limit was <0.7 µg/mL. TAT was measured by enzyme-
linked immunosorbent assay (ELISA) with a reference range of 0.1–5.0 ng/mL (Enzygnost
TATmicro; Siemens Healthcare Diagnostics Inc., Tokyo, Japan).
There were two patient groups: IPC group (67 patients) and fondaparinux (FPX) group (103
patients). During surgery, IPC was concurrently performed on all patients in both groups
under general anesthesia, and the patients were intravenously administered unfractionated
heparin (UFH) in a single dose of 20 IU/kg of body weight. IPC was postoperatively maintained
until the day patients started walking, usually 1-2 days after surgery, and this was the only
thromboprophylaxis for the IPC group. In addition to IPC, the patients in the FPX group were
also subcutaneously administered 2.5 mg of FPX daily for 14 days starting on postoperative
day 1. For the detection of postoperative VTE including PE and DVT, angiography of the
pulmonary artery and deep vein of the pelvis and the lower limbs was performed for all
patients on postoperative day 7 by 64-slice multidetector row computed tomography using a
nonionic contrast agent.
Postoperative VTE was detected in 17 (25%) of the IPC patients, and 8 (7%) of the FPX patients.
The difference in the frequency of VTE occurrence between the IPC and FPX groups was
statistically significant (p< 0.01). All DVT presented in calf veins, and there were no cases with
symptomatic DVT or PE.
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In the IPC group, plasma levels of SF on postoperative day 1 were significantly higher in
patients with VTE than in those without VTE (Figure 1, p< 0.01). Similar to SF, plasma levels
of PAI-1 on day 1 were also significantly higher in the patients with VTE in the IPC group
(Figure 1, p< 0.01). On the other hand, SF and PAI-1 levels showed similar tendencies in patients
with and without VTE in the FPX group (Figure 2). In both the IPC and the FPX group, plasma
D-dimer levels showed bimodal peaks that were evident on postoperative days 1 and 7. In the
IPC group, significant differences were found on postoperative day 7 (p< 0.01, Figures 1 and
2). IPC patients with VTE also had higher TAT levels on postoperative day 1 (p< 0.05).
Plasma levels of soluble fibrin (SF) (A), plasminogen activator inhibitor type 1 (PAI-1) (B), D-dimer (C), and thrombin-
antithrombin complex (TAT) (D) in patients who received only intermittent pneumatic compression were measured
preoperatively (pre-op) and on postoperative days 1 (POD1), 3 (POD3), 7 (POD7), and 14 (POD14). The boxes repre‐
sent the interquartile ranges. The perpendicular lines (whiskers) represent the 5th and 95th percentiles and the hori‐
zontal bars in the boxes indicate the median values. On the day after surgery, the plasma levels of SF, PAI-1, and TAT
were found to be significantly increased in the venous thromboembolism (VTE) group as compared with the non-VTE
group (p < 0.01, p < 0.01, p < 0.05, respectively). The changes in D-dimer levels showed bimodal peaks on postopera‐
tive days 1 and 7 in both groups. Significant differences were observed in the D-dimer levels measured on postopera‐
tive day 7 (p < 0.01).
Figure 1. Changes in coagulation and fibrinolysis markers in patients who received only intermittent pneumatic com‐
pression after total hip arthroplasty
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Plasma levels of soluble fibrin (SF) (A), plasminogen activator inhibitor type 1 (PAI-1) (B), D-dimer (C), and thrombin-
antithrombin complex (TAT) (D) in patients who received subcutaneous injections of fondaparinux sodium were
measured preoperatively (pre-op) and on postoperative days 1 (POD1), 3 (POD3), 7 (POD7), and 14 (POD14). The box‐
es represent the interquartile ranges. The perpendicular lines represent the 5th and 95th percentiles and the horizon‐
tal bars in the boxes indicate the median values. There were no statistically significant differences in the levels of SF,
PAI-1, D-dimer, and TAT between the patients with and without VTE in the fondaparinux group.
Figure 2. Changes in coagulation and fibrinolysis markers in patients who received subcutaneous injections of fonda‐
parinux sodium after total hip arthroplasty
Figure 3 shows the receiver operating characteristic (ROC) curve for each marker on postop‐
erative day 1 (for SF, PAI-1, and TAT) and day 7 (for D-dimer). The ROC curves provided the
cut-off levels for these markers, and the SF cut-off level was determined to be 19.8 µg/mL with
a sensitivity of 88% and a specificity of 62%. The cut-off level of PAI-1 was 53.5 ng/mL with a
sensitivity of 78% and a specificity of 72%, and that of TAT was determined to be 18.1 ng/mL
with a sensitivity of 85% and a specificity of 66%. Of these markers, multivariate logistic
regression analysis revealed SF and PAI-1 to have the strongest associations, statistically, with
a thrombotic tendency.
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In each diagram, the area under the ROC curve is shown, as well as the 95% confidence interval in parentheses.
Figure 3. Receiver operating characteristic curve analyses of the accuracies of quantitative soluble fibrin (SF), plasmi‐
nogen activator inhibitor type 1 (PAI-1), and thrombin-antithrombin complex (TAT) levels on postoperative day 1 and
D-dimer levels on day 7
Figure 4 shows the scatter graph of SF and PAI-1 levels, with 2 lines at each cut-off level.
These lines divide patients into 2 groups,  with higher and lower levels,  and these divi‐
sions provided a sensitivity of 100%, a specificity of 67%, and a positive predictive value
of 50% for postoperative VTE. In addition, when this criterion was applied to patients of
the FPX group, 7 of the 8 with VTE met the criterion, yielding a negative agreement rate
of 98.0% (48/49).
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Increases in either SF or PAI-1 on postoperative day 1 above their cut-off levels provided 100% sensitivity and 67%
specificity for predicting VTE when patients were not administered fondaparinux sodium postoperatively (A). In addi‐
tion, when this criterion was applied to patients who received subcutaneous injections of fondaparinux following sur‐
gery, 7 of 8 patients with VTE met the criterion, yielding a 98.0% (48/49) negative agreement rate (B).
Figure 4. Discriminating postoperative venous thromboembolism (VTE) using levels of soluble fibrin (SF) and plasmi‐
nogen activator inhibitor type 1 (PAI-1)
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As shown in the scatter graphs, pharmaco-prophylaxis reduced the incidence of VTE especially
in the high-risk group. In addition, the incidence of VTE in the low-risk group was not different
from those obtained with other methods of thromboprophylaxis. The blood analysis on the
day after surgery indicated almost half of patients to be in the low-risk group. It was suggested
that patients with low plasma levels of SF and PAI-1 might not need pharmaco-prophylaxis
following surgery. The blood analysis, which we have suggested as a means of risk assessment,
was very simple to use and would likely be acceptable to many institutions. However, further
investigation is necessary due to the small sample size in this study.
Highly invasive surgery has been shown to commonly result in a hypercoagulable state [16,
29], resulting in elevated plasma SF. SF reflects acute intravascular fibrin formation as well
because SF is one of the circulating materials contributing to fibrin clots [30]. PAI-1 is also
produced at the site of inflammation following tissue injury [18, 23]. It was suggested that
plasma levels of SF and PAI-1 in the early phase after surgery reflect an imbalance between
coagulation and fibrinolysis which contributes to excessive fibrin deposition in the vascular
wall [31]. We believe that the combined measurement of SF and PAI-1 on postoperative day 1
is a useful screening method for patients at high risk for postoperative VTE and for determining
whether pharmaco-prophylaxis after THA is indicated.
Because the results of SF and PAI-1 assays can be obtained within several hours on the day
after surgery, whether pharmaco-prophylaxis is indicated can be determined on postoperative
day 1. However, the optimal timing for the initiation of pharmaco-prophylaxis is one of the
issues raised by thromboprophylaxis, and the administration of anticoagulant agents follow‐
ing this screening test might be regarded as being relatively late. There has been debate in the
literature regarding the issue of how to maximize efficacy while minimizing bleeding risk [32]
because the peak efficacy of anticoagulant agents depends on the timing of the first injection
[33, 34]. According to a systematic review [33], the incidence of DVT was 19% in patients to
whom low-molecular-weight heparin (LMWH) was administered 12 hours before surgery,
12% in patients given LMWH during surgery, and 14% in those treated postoperatively. In our
study, low-dose UFH was administered once during surgery and postoperative anticoagula‐
tion was performed 24 hours after surgery. According to our results, the initiation of anticoa‐
gulation, as performed in this study, appears to be both reasonable and appropriate.
The present study has limitations. First, VTE could be initiated during the operation [35, 36],
in the postoperative period without mobilization [37], or 1-2 months after surgery [38, 39].
Thus, evaluations of VTE occurrence may vary depending on the timing of imaging tests,
duration of follow-up, or the duration of postoperative thromboprophylaxis. Second, our
study was limited to a single center, and the sample size was too small to draw conclusions
about the efficacy of our alternative prophylaxis regimen.
3. Summary
Individual risk assessment is becoming a widespread method for determining whether
prophylaxis, especially in patients undergoing major orthopedic surgery, is indicated. VTE
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developing after surgery might be induced by a hypercoagulable or regulated fibrinolytic state
during the early postoperative phase. Thus, the proposed screening test using SF and PAI-1
on the day after surgery may be of value in providing information about whether the coagu‐
lation state is unbalanced, and in predicting VTE following THA. We anticipate that selective
pharmacological thromboprophylaxis, based on the plasma levels of SF and PAI-1 on the first
postoperative day, will be achieved with an alternative thromboprophylaxis regimen.
Characteristics
IPC group
p value
FPX group
p valuePatients with
VTE
N = 17
Patients without
VTE
N = 50
Patients with
VTE
N = 6
Patients without
VTE
N = 97
Age, years 68 (8) 62 (12) N.S. 58 (8) 61 (12) N.S.
Gender: Male/Female,
no. 3/14 17/33 N.S. 6/0 21/76 N.S.
Weight, kg 58 (14) 58 (13) N.S. 59 (14) 58 (13) N.S.
Body mass index 24 (6) 23 (5) N.S. 24 (5) 24 (5) N.S.
Primary hip disease, no. N.S. N.S.
OA 15 36 4 79
RA 0 3 0 7
ANFH 2 6 2 11
PVS 0 1 0 0
Preoperative plasma
levels of:
Triglycerides, mg/dL 92 (35) 108 (40) N.S. 99 (32) 98 (41) N.S.
Total cholesterol,
mg/dL 228 (44) 199 (31) N.S. 202 (26) 222 (36) N.S.
Values are presented as means (SD). IPC, intermittent pneumatic compression; FPX, fondaparinux sodium; VTE, venous
thromboembolism; OA, osteoarthritis; RA, rheumatoid arthritis; ANFH, avascular necrosis of femoral head; PVS, pig‐
mented villonodular synovitis; N.S., not significant.
Table 1. Patient characteristics
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